No Data
Guolian Securities: Increased attention to tumor immunology, recommend focusing on targeted drugs such as PD1/IL2 in pharmaceutical companies.
With the increasing attention to tumor immunity, and the successive launch of advantageous products, bullish on PD1/IL2 and PD1/IL15 targeted drugs.
With 56% Ownership, Accuray Incorporated (NASDAQ:ARAY) Boasts of Strong Institutional Backing
Accuray to Report Fourth Quarter Fiscal 2024 Financial Results on August 14, 2024
IMS Shin-Matsudo Central General Hospital Completes First Patient Treatment With the ZAP-X Gyroscopic Radiosurgery Platform
Accuray Incorporated (ARAY): The Best Robotics Stock Under $10?
Global Radiation Therapy Market With Focus on LINAC: Insights & Forecast 2024-2028, Featuring Profiles of Ion Beam Applications, Siemens Healthineers, Accuray, Elekta, ViewRay and Hitachi - ResearchAndMarkets.com
Don't Ignore The Insider Selling In AccurayNo Data
